E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with chronic hepatitis B, HBeAg-negative, on treatment with nucleos(t)ide analogues. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10019654 |
E.1.2 | Term | Hepatic and hepatobiliary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary: To assess the efficacy of Peginterferon alfa-2a for 48 weeks used in monotherapy after 4 weeks of combination with nucleos(t)ide in patients with chronic hepatitis B, HBeAg-negative who present residual viremia or virological rebound during nucleos(t)ide analogues treatment. |
|
E.2.2 | Secondary objectives of the trial |
Secondary: To assess the safety of Peginterferon alfa-2a for 48 weeks used in monotherapy after 4 weeks of combination with nucleos(t)ide in patients with chronic hepatitis B, HBeAg-negative who present residual viremia or virological rebound during nucleos(t)ide analogues treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria: 1. Chronic hepatitis B anti-HBe positive or Cirrhosis Child-Pugh A5 without portal hypertension signs on analogue treatment 2. Age 18-65 years 3. HBV DNA > 60 IU/mL to 2,000 IU/mL (HBV DNA > 300 cp/mL to 10,000 cp/mL) at least six months of therapy OR HBV-DNA increase ³ 1log10 but < 20,000 IU/mL versus the previous HBV-DNA assessment performed within 4 weeks before 4. Able to participate, and willing to give written informed consent and to comply with the study restrictions |
|
E.4 | Principal exclusion criteria |
Exclusion criteria: 1. ALT > 10 ULN 2. Presence of cirrhosis with a Child-Pugh score > 5, esophageal varices &#8805; F2, history or evidence of ascites or bleeding 3. A positive result in HBeAg, HCV, anti-HDV or HIV tests 4. History or evidence of other causes of liver disease associated to HBV (haemochromatosis, alcoholic hepatitis, etc) 5. Autoimmune diseases; 6. A neutrophil count <1,500/mm3 or platelets <70,000/mm3 7. Haemoglobin <11.5 for women and 12.5 g/dL for men 8. Serum creatinine >1.5 the ULN 9. Significant renal disease 10. AFP >100 ng/mL; patients with AFP values >20 but <100 ng/mL can be enrolled if liver US is negative for nodules 11. Diagnosis of hepatocellular carcinoma 12. History or evidence of psychiatric disease, particularly of depression 13. Alcohol consumption >30 g/dL for men or 20 g/dL for women 14. Drug abuse 15. History of seizures or use of anti-epileptic drugs 16. Heart disease (NYHA 3 or 4) or other significant heart abnormality 17. Organ transplant recipients 18. Uncontrolled thyroid dysfunction 19. Retinal diseases 20. If female of child-bearing potential, a positive urine pregnancy test 21. Lactating women 22. Participation in an investigational drug study within three months prior to screening 23. Concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study 24. Any confirmed significant allergic reactions against any drug, or multiple allergies |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoint: The reduction of HBV-DNA levels to below 2,000 IU/mL (10,000 cp/mL) after 24 weeks of untreated follow-up period. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |